How will Lilly obesity pill rollout affect pricing and AI labs

Transcript

I am sitting here with Lucas Monitor, say he is the CFO over at Eli Lilly. First off, it's great to see you, Lucas. Thank you for having me. So we have to talk about what you're doing with Nvidia, but we have to start first with what's going on with pills. Obesity. Weight loss pills. So Novo Nordisk, the big news at the end of last year was that th... Read More

Key Insights

• Lilly is on track for obesity pill regulatory approval in the US as early as Q2.
• The company expects expanded market access will grow the total patient pool for obesity meds.
• Lilly plans to leverage both injectables and direct to patient options to reach more patients.
• The direct Lilly platform already serves over 1 million patients, indicating strong distribution potential.
• Pricing strategies include a potential $50 copay for Medicare recipients, signaling broader payer access.
• The company is pursuing numerous early phase deals, with 50 deals signed last year to strengthen its pipeline.
• AI collaboration with Nvidia amounts to up to $1 billion over five years to build an AI lab and accelerate discovery.
• Beyond obesity, Lilly highlights oncology, neurodegeneration, and immunology as key growth areas with data readouts planned this year.
• More videos from this channel:
  • How do bond yields move when the Fed is expected to hike tomorrow
  • What happens to rates when Warsh drops forward guidance
  • Why Young Americans Embrace the Treat Economy
• More from this channel: Bloomberg Television

Questions & Answers

Q: What is Lilly’s timeline for obesity pill regulatory approval and how might it affect pricing?

Lilly is on track for regulatory approval as early as the second quarter this year, with plans to price and structure access in a way that could include Medicare participation. The company mentioned a potential $50 copay for patients on certain plans, aiming to broaden access and drive uptake while balancing commercial goals. This signals a push to align incentives for patients, providers, and payers as the product enters the market.

Q: How does Lilly view the impact of obesity pills on market size and cannibalization of injectables?

Lilly believes the obesity pill will expand the total addressable market both in the US and globally by appealing to patients who prefer non-injectable options and by enlarging the overall patient base. While injectables remain important, the oral or alternate delivery option is expected to grow total demand and complement existing therapies rather than cannibalize them.

Q: What is the nature of Lilly’s deal with the Trump administration and when might the effects be felt?

Lilly noted a deal with the Trump administration aimed at lowering prices for weight loss drugs, tied to the quick burn device and broader access measures. They expect approval and practical effects within the next few months, with rollout and payer partnerships potentially accelerating in the near term, improving patient access and market dynamics.

Q: What does Lilly’s commentary imply about future Medicare access and costs for anti obesity medications?

Lilly highlighted the Medicare opportunity to provide access for anti obesity medications with low patient costs, potentially as little as $50. The emphasis on Medicare access suggests a strategic focus on payer inclusion and affordability, which could expand patient reach and support sustained demand, especially if coverage details are confirmed in 2025.

Q: What is the scope of Lilly’s AI initiatives with Nvidia and what is the expected impact?

Lilly announced a five year commitment totaling up to $1 billion with Nvidia to build a new AI lab and advance discovery. The collaboration brings scientists and engineers from both companies to work on AI driven drug discovery, aiming to transform workflows, speed up research cycles, and uncover new therapeutic opportunities across multiple disease areas.

Q: How is Lilly planning to grow its pipeline beyond obesity and diabetes markets?

Lilly is pursuing ongoing M&A and expanding into core therapeutic areas such as oncology, neurodegeneration, and immunology. The strategy emphasizes early phase deals and platform investments that broaden capabilities and accelerate internal pipeline development, providing a diversified growth trajectory beyond obesity and diabetes.

Q: What are the key catalysts investors should watch for this year besides obesity?

Investors should watch for topline data readouts in oncology, potential readouts in native insulin programs, and incentives driven studies that may yield results later this year or in 2027. These events, alongside ongoing deals and AI driven productivity gains, could signal meaningful momentum across Lilly’s broader therapeutic areas.

Q: What does Lilly say about profitability and sustainable growth in the context of rapid expansion?

Lilly states that it is not targeting specific profitability levels but focusing on sustainable growth through a robust pipeline and capital deployment. The emphasis is on reinvesting earnings to expand therapeutic areas, accelerate discovery, and strengthen the portfolio, aiming for durable long term profitability rather than short term margin targets.

Summary & Key Takeaways

• Lilly foresees near term obesity pill approval and expansion of access through Medicare with a possible $50 copay by mid 2025 to mid 2026.

• AI driven discovery is a major focus, with a new lab in Silicon Valley funded by Nvidia collaboration to accelerate pipeline development.

• The company emphasizes ongoing M&A and a large pipeline across oncology, neurodegeneration, and immunology as core growth drivers.